{"nctId":"NCT04662801","briefTitle":"Weight Regain Treatment Post-Bariatric Surgery","startDateStruct":{"date":"2021-08-05","type":"ACTUAL"},"conditions":["Obesity, Overweight"],"count":26,"armGroups":[{"label":"Behavioral Weight Loss","type":"EXPERIMENTAL","interventionNames":["Behavioral: Behavioral Weight Loss (BWL)","Behavioral: Early Responder: BWL continued"]},{"label":"Behavioral Weight Loss + Medication","type":"EXPERIMENTAL","interventionNames":["Behavioral: Behavioral Weight Loss (BWL)","Combination Product: Early Non-responder: BWL continued with medication added"]}],"interventions":[{"name":"Behavioral Weight Loss (BWL)","otherNames":[]},{"name":"Early Responder: BWL continued","otherNames":[]},{"name":"Early Non-responder: BWL continued with medication added","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Be in the age range ≥18 years of age and ≤70 years of age\n* Have a BMI ≥30 (or BMI ≥27 with a medical comorbidity) and ≤50 kg/m2\n* Have had laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy\n* Experiencing weight regain after bariatric surgery\n* Be an otherwise healthy subject without uncontrolled medical problems, as determined by the study physician and medical co-investigators (physical examination, laboratory studies).\n* Read, comprehend, and write English at a sufficient level to complete study-related materials.\n* Provide a signed and dated written informed consent prior to study participation.\n* Be available for participation in the study for up to 3 months.\n\nExclusion Criteria:\n\n* Has a predisposition to seizures (e.g., subject with a history or evidence of seizure disorder, febrile seizures during childhood, brain tumor, cerebrovascular disease, or significant head trauma; has a family history of idiopathic seizure disorder or is currently being treated with medications or treatment regimens that lower seizure threshold).\n* Has a history of anorexia nervosa or history of bulimia nervosa.\n* Is currently taking a medication that is a contraindication to NB medication (e.g., MAOI, opiates).\n* Is currently using other medications for weight loss.\n* Has a history of allergy or sensitivity to bupropion or naltrexone.\n* Has a co-existing psychiatric condition that requires hospitalization or more intensive treatment (such as bipolar mood disorders, psychotic illnesses, or severe depression)\n* Has untreated hypertension with a seated systolic blood pressure \\> 160 mmHg, diastolic blood pressure \\> 100 mmHg, or heart rate \\> 100 beats/minute.\n* Has a history of congenital heart disease, cardiovascular disease, cardiac arrhythmias requiring medication, or a history of cerebrovascular pathology including stroke.\n* Has current uncontrolled hypertension.\n* Has current uncontrolled Type I or Type II diabetes mellitus.\n* Has untreated hypothyroidism with a TSH \\> 1.5 times the upper limit of normal for the test laboratory with repeat value that also exceeds this limit.\n* Has gallbladder disease.\n* Has a history of severe renal, hepatic, neurological, chronic pulmonary disease, or any other unstable medical disorder.\n* Has a recent history of drug or alcohol dependence (since having bariatric surgery).\n* Is currently in active treatment for eating or weight loss.\n* Is currently participating in another clinical study in which the subject is or will be exposed to an investigational or a non-investigational drug or device.\n* Is breast-feeding or is pregnant or is not using a reliable form of birth control.\n* Reports active suicidal or homicidal ideation.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Body Mass Index","description":"BMI is calculated using measured height and weight- kg/m2.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.12","spread":"4.57"},{"groupId":"OG001","value":"40.48","spread":"4.89"}]}]}]},{"type":"SECONDARY","title":"Eating Disorder Psychopathology","description":"Eating-disorder psychopathology is a continuous variable as assessed by the global score of the Eating Disorder Examination/Eating Disorder Examination-Questionnaire. Scores range from 0-6 (0=no eating-disorder psychopathology; 6=severe eating-disorder psychopathology).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.53","spread":"0.80"},{"groupId":"OG001","value":"1.46","spread":"0.94"}]}]}]},{"type":"SECONDARY","title":"Food Craving","description":"Food craving will be assessed by the Food Craving Inventory (FCI). FCI scores range from 1-5, with higher scores indicative of greater craving.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.65","spread":"0.49"},{"groupId":"OG001","value":"1.57","spread":"0.29"}]}]}]},{"type":"SECONDARY","title":"Depressive Symptoms","description":"Depressive symptoms will be assessed by the Patient Health Questionnaire-9. The range is 0-27, which higher scores indicative of greater depressive symptomatology","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.89","spread":"5.21"},{"groupId":"OG001","value":"3.67","spread":"2.58"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":12},"commonTop":["Nausea","Dry mouth","Constipation","Diarrhea","Dizziness"]}}}